Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Scilex Holding Company

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PALO ALTO, CALIF., OCT. 01, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT HAS REPURCHASED 3,130,000 WARRANTS TO PURCHASE SHARES OF SCILEX COMMON STOCK HAVING AN EXERCISE PRICE OF $0.01 PER SHARE (WARRANTS) FROM ORAMED PHARMACEUTICALS INC. (ORAMED) FOR $13,000,000. AS PREVIOUSLY DISCLOSED, SCILEX ENTERED INTO AN OPTION AGREEMENT WITH ORAMED FOR THE REPURCHASE OF WARRANTS, PURSUANT TO WHICH, AMONG OTHER THINGS, ORAMED GRANTED AN OPTION TO SCILEX TO REPURCHASE 6,500,000 WARRANTS IN TWO TRANCHES FOR AN AGGREGATE PURCHASE PRICE OF $27,000,000. SCILEX CONTINUES TO HAVE THE OPTION TO REPURCHASE THE REMAINING 3,370,000 WARRANTS FROM ORAMED FOR $14,000,000 ON OR BEFORE DECEMBER 31, 2025.

SCILEX HOLDING COMPANY ANNOUNCES THE COMPLETION OF THE FIRST TRANCHE OF THE ORAMED PHARMACEUTICALS, INC. WARRANT REPURCHASE

BEAVERTON, ORE.--(BUSINESS WIRE)--DATAVAULT AI INC. (NASDAQ: DVLT), A LEADER IN AI-DRIVEN DATA VISUALIZATION, VALUATION, AND MONETIZATION, TODAY ANNOUNCED THE CLOSING OF THE INITIAL TRANCHE OF THE PREVIOUSLY ANNOUNCED $150 MILLION BITCOIN (BTC) INVESTMENT FROM SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX). UNDER THE TERMS OF THE AGREEMENT, SCILEX IS EXPECTED TO RECEIVE UP TO 278,914,094 SHARES OF DATAVAULT COMMON STOCK AT AN EFFECTIVE PURCHASE PRICE OF $0.5378 PER SHARE, SUBJECT TO ADJUSTMENT.

DATAVAULT AI ANNOUNCES CLOSING OF INITIAL TRANCHE INVESTMENT FROM SCILEX HOLDING COMPANY

PALO ALTO, CALIF. , SEPT. 26, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT HAS CLOSED THE INITIAL TRANCHE OF ITS PREVIOUSLY ANNOUNCED $150 MILLION BITCOIN (BTC) INVESTMENT IN DATAVAULT AI INC. (NASDAQ: DVLT, DATAVAULT), PURSUANT TO WHICH SCILEXIS EXPECTED TO RECEIVE UP TO AN AGGREGATE OF 278,914,094 SHARES OF DATAVAULT COMMON STOCK (AT AN EFFECTIVE PURCHASE PRICE OF$0.5378PER SHARE) (SUBJECT TO ADJUSTMENT FOR STOCK SPLITS AND SIMILAR TRANSACTIONS). AT THE CLOSING OF THIS INITIAL TRANCHE, SCILEX RECEIVED 15,000,000 SHARES OF DATAVAULT COMMON STOCK WITH THE REMAINDER TO BE ISSUED IN A SECOND TRANCHE IN THE FORM OF A PRE-FUNDED WARRANT TO PURCHASE DATAVAULT COMMON STOCK, SUBJECT TO APPROVAL BY DATAVAULT'S STOCKHOLDERS OF, AMONG OTHER THINGS, THE ISSUANCE OF DATAVAULT SHARES TO SCILEX IN EXCESS OF 19.99% OF DATAVAULT'S TOTAL PRE-FINANCING SHARES OUTSTANDING.

SCILEX HOLDING COMPANY ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED INITIAL TRANCHE INVESTMENT IN DATAVAULT AI

PALO ALTO, CALIF., SEPT. 25, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO MAKE A $150 MILLION BITCOIN (BTC) INVESTMENT IN DATAVAULT AI INC. (NASDAQ: DVLT, DATAVAULT), WHICH IS INTENDED TO PROVIDE GROWTH CAPITAL TO DATAVAULT TO ACCELERATE ITS SUPERCOMPUTING INFRASTRUCTURE, EXPAND INDEPENDENT DATA EXCHANGES, AND UNLOCK NEW REVENUE STREAMS.

SCILEX HOLDING COMPANY ANNOUNCES $150 MILLION STRATEGIC BITCOIN INVESTMENT IN DATAVAULT AI

PALO ALTO, CALIF., SEPT. 25, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT HAS CLOSED ITS PREVIOUSLY DISCLOSED TRANSACTION PURSUANT TO A SECURITIES PURCHASE AGREEMENT (SPA) WITH AN INSTITUTIONAL INVESTOR FOR THE EXCHANGE OF $200 MILLION OF COMMON STOCK OF ITS MAJORITY OWNED SUBSIDIARY, SEMNUR PHARMACEUTICALS, INC. (SEMNUR) (OTC: SMNR, SMNRW), HELD BY SCILEX FOR $200 MILLION IN BITCOIN (BTC), REPRESENTING A TOTAL OF 12,500,000 SHARES OF SEMNUR COMMON STOCK AT A PRICE OF $16.00 PER SEMNUR SHARE. SCILEX HAS NOW RECEIVED $200 MILLION IN BITCOIN IN ITS CRYPTOCURRENCY ACCOUNT.

SCILEX ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-DILUTIVE VALUE ENHANCING TRANSACTION WITH AN INSTITUTIONAL INVESTOR FOR THE EXCHANGE OF $200 MILLION OF COMMON STOCK OF SEMNUR PHARMACEUTICALS, INC. HELD BY SCILEX HOLDING COMPANY FOR $200 MILLION IN BITCOIN

PALO ALTO, CALIF., SEPT. 24, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT HAS SIGNED A NON-BINDING, NON-EXCLUSIVE MEMORANDUM OF UNDERSTANDING (THE MOU) WITH BICONOMY.COM (BICONOMY) WITH RESPECT TO FUTURE CRYPTOCURRENCY AND TREASURY MANAGEMENT STRATEGIES, INCLUDING IN THE FOLLOWING AREAS:

SCILEX HOLDING COMPANY ANNOUNCES IT HAS ENTERED INTO A MEMORANDUM OF UNDERSTANDING WITH BICONOMY.COM TO COLLABORATE ON FUTURE CRYPTOCURRENCY STRATEGIES AND TREASURY MANAGEMENT

PALO ALTO, CALIF., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- SEMNUR PHARMACEUTICALS, INC. (SEMNUR OR THE COMPANY) (OTC: SMNR, SMNRW) , A CLINICAL LATE-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF NOVEL NON-OPIOID PAIN THERAPIES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT (SPA) WITH THE INSTITUTIONAL INVESTOR FOR THE PURCHASE OF $100 MILLION OF SHARES OF SEMNUR COMMON STOCK IN EXCHANGE FOR $100 MILLION IN BITCOIN (BTC).

SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY OWNED SUBSIDIARY OF SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX) ANNOUNCES SIGNING OF A SECURITIES PURCHASE AGREEMENT WITH AN INSTITUTIONAL INVESTOR FOR THE PURCHASE OF $100 MILLION OF SHARES OF SEMNUR COMMON STOCK IN EXCHANGE FOR $100 MILLION IN BITCOIN

PALO ALTO, CALIF., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- SEMNUR PHARMACEUTICALS, INC. (SEMNUR OR THE COMPANY) (OTC: SMNR, SMNRW) , A CLINICAL LATE-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF NOVEL NON-OPIOID PAIN THERAPIES AND DENALI CAPITAL ACQUISITION CORP (DENALI), A SPECIAL PURPOSE ACQUISITION COMPANY, ANNOUNCED THE CLOSING OF THEIR PREVIOUSLY ANNOUNCED BUSINESS COMBINATION (THE "BUSINESS COMBINATION") ON SEPTEMBER 22, 2025.

SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY-OWNED SUBSIDIARY OF SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX), AND DENALI CAPITAL ACQUISITION CORP. ANNOUNCED THE CLOSING OF THEIR PREVIOUSLY ANNOUNCED BUSINESS COMBINATION ON SEPTEMBER 22, 2025

PALO ALTO, CALIF., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX) , AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS MAJORITY-OWNED SUBSIDIARY, SEMNUR PHARMACEUTICALS, INC. (SEMNUR), AND DENALI CAPITAL ACQUISITION CORP (DENALI), A SPECIAL PURPOSE ACQUISITION COMPANY, ANNOUNCED THE CLOSING OF THEIR PREVIOUSLY ANNOUNCED BUSINESS COMBINATION (THE "BUSINESS COMBINATION").

SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY-OWNED SUBSIDIARY OF SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX), AND DENALI CAPITAL ACQUISITION CORP. ANNOUNCE THE CLOSING OF THEIR PREVIOUSLY ANNOUNCED BUSINESS COMBINATION

PALO ALTO, CALIF, SEPT. 04, 2025 (GLOBE NEWSWIRE) -- SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY-OWNED SUBSIDIARY OF SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT THE SHAREHOLDERS OF DENALI CAPITAL ACQUISITION CORP (DENALI) APPROVED THE PREVIOUSLY ANNOUNCED BUSINESS COMBINATION WITH SEMNUR (THE "BUSINESS COMBINATION").

SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY-OWNED SUBSIDIARY OF SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX), AND DENALI CAPITAL ACQUISITION CORP. ANNOUNCE APPROVAL FROM DENALI'S SHAREHOLDERS OF THE PREVIOUSLY ANNOUNCED BUSINESS COMBINATION

PALO ALTO, CALIF., AUG. 21, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS MAJORITY-OWNED SUBSIDIARY, SEMNUR PHARMACEUTICALS, INC. (SEMNUR), AND DENALI CAPITAL ACQUISITION CORP (DENALI) HAVE ENTERED INTO A PURCHASE AGREEMENT (PURCHASE AGREEMENT) WITH AN INVESTOR FOR A $20 MILLION PRIVATE PLACEMENT, THE PROCEEDS OF WHICH WILL BE USED TO ADVANCE THE SECOND PHASE 3 CLINICAL TRIAL FOR THE DEVELOPMENT OF SP-102 (10 MG, DEXAMETHASONE SODIUM PHOSPHATE VISCOUS GEL) (SEMDEXA OR SP-102), FOR THE TREATMENT OF LRP/SCIATICA.

SCILEX HOLDING COMPANY (NASDAQ: SCLX) ANNOUNCES ITS MAJORITY-OWNED SUBSIDIARY, SEMNUR PHARMACEUTICALS, INC. (SEMNUR), AND DENALI CAPITAL ACQUISITION CORP. HAVE ENTERED INTO A PURCHASE AGREEMENT WITH AN INVESTOR FOR A $20 MILLION PRIVATE PLACEMENT AT $16.00 PER SHARE AND JAISIM SHAH, SCILEX'S CEO AND PRESIDENT, WILL BE DEDICATED TO SEMNUR ON A FULL TIME BASIS TO RAPIDLY ADVANCE SP-102 TO REGULATORY APPROVAL AND COMMERCIALIZATION FOR THE TREATMENT OF LUMBOSACRAL RADICULAR PAIN (LRP)/SCIATICA

PALO ALTO, CALIF., AUG. 13, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX) , AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT THE REGISTRATION STATEMENT ON FORM S-4 (THE REGISTRATION STATEMENT), RELATED TO THE PREVIOUSLY ANNOUNCED PROPOSED BUSINESS COMBINATION (THE BUSINESS COMBINATION) BETWEEN DENALI CAPITAL ACQUISITION CORP. ("DENALI") (OTCB: DNQAF), A SPECIAL PURPOSE ACQUISITION COMPANY, AND SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY-OWNED SUBSIDIARY OF SCILEX, HAS BEEN DECLARED EFFECTIVE BY THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC").

SCILEX HOLDING COMPANY (NASDAQ: SCLX) ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT ON FORMS-4 FOR THE PROPOSED BUSINESS COMBINATION OF DENALI CAPITAL ACQUISITION CORP. AND SEMNUR PHARMACEUTICALS, INC., A MAJORITY-OWNED SUBSIDIARY OF SCILEX

Scilex Holding Company

SCLX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Scilex Holding Company

SCLX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SCLX